V
49.61
-0.04 (-0.08%)
| Previous Close | 49.65 |
| Open | 49.91 |
| Volume | 627,323 |
| Avg. Volume (3M) | 1,695,738 |
| Market Cap | 6,494,259,712 |
| Price / Book | 2.25 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Diluted EPS (TTM) | -3.99 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 17.70 |
| Operating Cash Flow (TTM) | -459.78 M |
| Levered Free Cash Flow (TTM) | -419.13 M |
| Return on Assets (TTM) | -14.53% |
| Return on Equity (TTM) | -19.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vaxcyte, Inc. | Bullish | Bearish |
AIStockmoo Score
1.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.68% |
| % Held by Institutions | 117.40% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 85.00 (BTIG, 71.34%) | Buy |
| Median | 61.50 (23.97%) | |
| Low | 38.00 (Goldman Sachs, -23.40%) | Hold |
| Average | 61.50 (23.97%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 37.55 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 10 Nov 2025 | 85.00 (71.34%) | Buy | 42.92 |
| Goldman Sachs | 12 Sep 2025 | 38.00 (-23.40%) | Hold | 32.17 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |